MDACC Study No:2006-0417 ( NCT No: NCT00359086)
Title:A Phase II Study of MGCD0103 Given Three-Times Weekly In Patients With Relapsed And Refractory Lymphoma
Principal Investigator:Yasuhiro Oki
Treatment Agent:MGCD0103
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn the effectiveness of
MGCD0103 in the treatment of patients with lymphoma that has relapsed or is
refractory. The safety of this drug will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:MGCD0103
Treatment Location:Independent Multicenter Arrangements
Estimated Length of Stay in Houston:N/A
Supported By:N/A
Return Visit:Patients will have 4 visits on Cycle 1 (on Days 1, 8, 15 and 22) and 2 visits
on subsequent cycles (on Days 1 and 15) for up to 1 year. Patients should be
seen 30 days after completion of therapy.
Home Care:Patients may take MGCD0103 gelcaps by mouth at home.

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Yasuhiro Oki
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults